Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation
Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2904-2917
DOI: 10.1021/acs.jmedchem.2c01941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.02.2023. Verfasst von Haibo Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, Wisconsin 53705 …. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Nuclear Proteins, Proteolysis, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Wisconsin Alumni Research Foundation, Center for Scientific Review.
Abstract (Originalsprache)
Glutarimides such as thalidomide, pomalidomide, and lenalidomide are the most frequently used ligands to recruit E3 ubiquitin ligase cereblon (CRBN) for the development of proteolysis-targeting chimeras (PROTACs). Due to the rapid and spontaneous racemization of glutarimides, most CRBN-recruiting PROTACs are synthesized as a mixture of racemates or diastereomers. Since the (S)-enantiomer is primarily responsible for binding to CRBN, the existence of the largely inactive (R)-enantiomer complicates the drug development process. Herein, we report that substituted achiral phenyl dihydrouracil (PDHU) can be used as a novel class of CRBN ligands for the development of PROTACs. Although the parent PDHU has a minimal binding affinity to CRBN, we found that some substituted PDHUs had a comparable binding affinity to lenalidomide. Structural modeling provided a further understanding of the molecular interactions between PDHU ligands and CRBN. PDHUs also have greater stability than lenalidomide. Finally, potent BRD4 degraders were developed by employing trisubstituted PDHUs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, Wisconsin 53705 United States.
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States.
ORCID-Profile: Haibo Xie, Brett L Roberts, Weiping Tang
Förderung
- NIGMS NIH HHS
- Wisconsin Alumni Research Foundation
- Center for Scientific Review
- University of Wisconsin-Madison
Zitieren
APA
Xie, H., Li, C., Tang, H., Tandon, I., Liao, J., Roberts, B. L., Zhao, Y., & Tang, W. (2023). Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. Journal of Medicinal Chemistry, 66(4), 2904-2917. https://doi.org/10.1021/acs.jmedchem.2c01941
Vancouver
Xie H, Li C, Tang H, Tandon I, Liao J, Roberts BL, et al. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. Journal of Medicinal Chemistry. 2023;66(4):2904-2917. doi:10.1021/acs.jmedchem.2c01941
BibTeX
@article{Xie2023,
author = {Xie, Haibo and Li, Chunrong and Tang, Hua and Tandon, Ira and Liao, Junzhuo and Roberts, Brett L and Zhao, Yu and Tang, Weiping},
title = {Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {4},
pages = {2904--2917},
doi = {10.1021/acs.jmedchem.2c01941}
}
EUVIMED